Mesoblast stock
MESONASDAQMesoblast Limited, HealthcareISIN US5907174016
37Score 37 out of 100, Weak
Price and trend
40 / 100
Price history
−17% in one yearThe chart shows daily closes over 18 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 14% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 38% below its 52-week high. Largest decline in 18 years: 98% (October 2011 to January 2024).
Chart figures for advanced users
- SMA 50$14.40
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.23
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.95
- The lowest closing price of the last twelve months.
- Resistance$20.96
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Mesoblast Limited belongs to the Biotechnology industry (Australia) and, with a market value of $1.7B, is number 143 of 289 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2026 it reported revenue of $120.79M (up 602.3% year on year) and a loss of $57.76M.
Show more
- MEQIRI Score 37 out of 100 (Weak): rank 580 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 74.5% a year since 2021, Biotechnology median 19.4%.Growth 70
Weaknesses
- DilutionShare count up 114% since 2021.Capital allocation 18
- Loss-makingLoss of $57.5M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$44.73M over the last 12 months.Fundamentals 17
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 39 to 37.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Revenue has grown strongly since 2007, at around 25% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 84%, operating −43%, net −48%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Mar 2027in 111 days
- Last reported
- 26 Aug 2026below expectations
Analyst estimates
- Earnings per share
- −0.16+16.6%
- Revenue
- $196.1M−6.7%
- Earnings per share
- 0.26+70.4%
- Revenue
- $347.67M−9.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +5.8%The company expects double-digit growth over the coming 12 months and a lower cash burn than in 2026, with no comparison to earlier expectations.
“But we certainly expect to see double-digit growth in the coming 12-month period.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 26 Aug 2026 (fiscal Q4 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- George GregoryPurchase
9 Apr 2026, Board
- Shares
- 595,000
- Price
- $14.37
- Value
- $8.55M
Shares and prices per ordinary share as filed with the SEC, not per depositary receipt.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Mesoblast
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Kailera TherapeuticsKLRA $1.72B41
- Stoke TherapeuticsSTOK $1.71B37
- Taysha Gene TherapiesTSHA $1.71B35
- Nurix TherapeuticsNRIX $1.7B68
- PrecigenPGEN $1.67B54
- Ultragenyx PharmaceuticalRARE $1.66B38
- NanobiotixNANO.PA $1.64B38
- SELLAS Life Sciences GroupSLS $1.62B35
ETFs that hold Mesoblast
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.05% | 0.35% | €1.25B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2012)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.